Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-28
2005-06-28
Spivack, Phyllis (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S428000, C514S429000
Reexamination Certificate
active
06911456
ABSTRACT:
The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula Iwherein the variables A, B, Y, D, Z1, G and e are as described herein.
REFERENCES:
patent: 3234090 (1966-02-01), Huebner
patent: 3274213 (1966-09-01), Lednicer
patent: 3277106 (1966-10-01), Bencze
patent: 3293263 (1966-12-01), Lednicer
patent: 3320271 (1967-05-01), Lednicer
patent: 3396169 (1968-08-01), Lednicer
patent: 3483293 (1969-12-01), Duncan
patent: 3522319 (1970-07-01), Bencze et al.
patent: 3567737 (1971-03-01), Lednicer
patent: 3862232 (1975-01-01), Lednicer
patent: 3875242 (1975-04-01), Lednicer
patent: 4133814 (1979-01-01), Jones et al.
patent: 4358593 (1982-11-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5470854 (1995-11-01), Angerer et al.
patent: 5472962 (1995-12-01), Koizumi et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5484798 (1996-01-01), Bryant et al.
patent: 5510357 (1996-04-01), Palkowitz
patent: 5532382 (1996-07-01), Carlson et al.
patent: 5552412 (1996-09-01), Cameron et al.
patent: 5567828 (1996-10-01), Dodge
patent: 6153622 (2000-11-01), Cameron et al.
patent: 6204286 (2001-03-01), Cameron et al.
patent: 2001/0025051 (2001-09-01), Cameron et al.
patent: 2002/0132816 (2002-09-01), Cameron et al.
patent: 0605193 (1993-12-01), None
patent: 0617030 (1994-03-01), None
patent: 0838459 (1997-10-01), None
patent: 0792642 (2001-08-01), None
patent: 1107016 (1966-03-01), None
patent: WO 9307149 (1993-04-01), None
patent: WO 9510513 (1995-04-01), None
patent: WO 9621656 (1996-07-01), None
patent: WO 9716434 (1997-05-01), None
patent: WO 9833499 (1998-08-01), None
McGuire et al., Chapter 93/ Breast Cancer from Pharmacotherapy, A Pathophysiologic Approach, Editors, DiPiro, New York, (1989), pp. 1345-1358.
D. Lednicer, et al.,J. Med. Chem., “Mammalian Antifertility Agents. VI. A Novel Sequence for the Preparation of 1,2-Disubstitued 3,4-Dihydronaphthalenes”, vol. 12 pp. 881-884 (1969).
D. Lednicer, et al.,J. Med. Chem., “Mammalian Antifertility Agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-Tetrahydro-1- naphthols1,2”, vol. 10, pp. 78-84 (1967).
W.L. Bencze, et al.,J. Med. Chem., “Synthetic Estrogens, Implantation Inhibitors, and Hypocholesterolemic Agents. I. Tetrahydronaphthalene Series”, vol. 10, pp. 138-144 (1967).
M. P. Wentland, et al.,J. Med. Chem., “Synthesis and Antidepressant Properties of Novel 2-Substitued 4,5-Dihydro-1H-imidazole Derivaties”, vol. 30, pp. 1482-1489 (1987).
K. Nagarajan, et al.Indian Journal of Chemistry, Antiimplantation Agents: Part IIa—1,2-Diaryl-1,2,3,4-tetrahydroisoquinolinesb.c.vol. 24B, pp. 83-97 (1985).
W.L. Bencze, et al.J. Med. Chem., “Selective Adrenal Cortical and Gonadal Inhibitors”, vol. 5, pp. 1298-1306 (1692).
Gayland P. Spencer,Journal of Natural Products, “The Effects of a Terpene Aldehyde-Ester from Eryngium Paniculatum and Analogs on Velvetleaf Germination”, vol. 49, No. 5, pp. 924-926 (1986).
C. Tilford, et al.,Journal of American Chemical Society, “Aminoesters of 1-Substitued Alicyclic Carboxylic Acids”, vol. 71 pag 1705-1709 (1949).
M. Gordaliza, et al.,Bioorganic and Medicinal Chemistry Letters, “Selective Cytotoxic Cyclolignans”, vol. 5, No. 21, pp. 24 2468 (1995).
Robert C. Jones,Acta Endocrinologica, “The Effect of A Luteinizing Hormone-Releasing Hormone Antagonist On Experimental Endometriosis in the Rat”, vol. 114 pp. 379-382 (1987).
M. T. Tzukerman, et al.,Molecular Endocrinology, “Human Estrogen Receptor Transactivational Capacity Is Determined by both Cellular and Promoter Context and Mediated by Two Functionally Distinct Intramolecular Regions”, vol. 8 No. 1, pp. 21-30 (1994).
R.L. Metcalf, et al.,Journal of Agricultural Food Chemistry, “Mode of Action of Carbamate Synergists”, vol. 14 No. 6, pp. 5 562 (1966).
Osteoporosis Conference, SCRIP No. 1812/13, Apr. 16th/20thpp. 29-30 (1993).
C.D. Jones, et al.,J. Med. Chem., “Antiestrogens. 2. Structure-Activity Studies in a Series of 3-arolyl-2-arylbenzo[b]thiopene Derivatives Leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride (LY 156758), a Remarkably Effective Estrogen Antagonist With Only Minimal Intrinsic Estrogenicity”, vol. 27, pp. 1057-1066 (1984).
Drug Design, vol. VIII, New York: Academic Press, New York, New York, 1979, pp. 182-191.
Cohen, et al., “LAS, as Novel Selective Estrogen Receptor Modulator with Chemopreventive and Therapeutic Activitiy in the N- Nitroso-N-mehtylurea-induced Rat Mammary Tumor Model”,Cancer Research61, pp. 8683-8688 (2001).
“Cancer Facts”,Breast Cancer Prevention Studies, Cancer Facts 4.18, Breast Cancer Institute (2002).
Nolvadex Tamoxifen CitrateRev 06-03 Package Insert (2003).
“Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer”,Clinical Trials (PDQ), National Cancer Institute 1999 (last modified 2003).
MacLean David B.
Thompson David D.
Benson Gregg C.
Delacroix-Muirheid Cybille
Pfizer Inc
Richardson Peter C.
Spivack Phyllis
LandOfFree
Use of estrogen antagonists and estrogen agonists in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of estrogen antagonists and estrogen agonists in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of estrogen antagonists and estrogen agonists in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3518493